Handelsavisen
prelaunch
Companies ›Healthcare ›3613.HK
36
3613.HK — HKEX Pharmaceuticals

Beijing Tong Ren Tang Chinese Medicine Co Ltd

HK$7,14
Open in Charts → Attach watcher ⌖
— —
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
6,0B HKD
P/E
—
EV / Rev
—
Div yield
5,04 %
Op margin
31,2 %
ROE
9,5 %
Net margin
26,2 %
Debt / equity
0,03
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical company that develops, produces, and sells traditional Chinese medicine products, primarily in the healthcare sector.

Business. Beijing Tong Ren Tang Chinese Medicine Co Ltd (3613.HK) is a pharmaceutical company headquartered in Beijing that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target10,25

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
10,25
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership
—
not yet wired
Profitability→
9,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 3613.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 3613.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Beijing Tong Ren Tang Chinese Medicine Co Ltd (3613.HK) is a pharmaceutical company headquartered in Beijing that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 19.65 and cash and equivalents amounting to HKD 2.23 billion, which significantly exceeds its total liabilities of HKD 472.85 million. The price-to-book ratio of 1.43 and a low debt-to-equity ratio of 0.03 indicate a conservative capital structure with minimal leverage.

    Profitability metrics show a return on equity (ROE) of 9.48% and a return on assets (ROA) of 8.52%, both of which are strong indicators of efficient asset utilization and profitability. The gross profit margin of 61.16% (calculated from gross profit of HKD 925.58 million on revenue of HKD 1.51 billion) and an operating margin of 31.20% (calculated from operating income of HKD 472.24 million) suggest robust cost control and pricing power.

    The company's revenue is primarily concentrated in its core pharmaceutical business, with no disclosed geographic diversification. As a result, it is highly exposed to market conditions in its primary operating region. No material revenue concentration risks are currently flagged, but the lack of geographic diversification could pose a risk in the event of regional economic or regulatory shifts.

    Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant revenue growth or decline projected in the current or next fiscal year. The current price-to-earnings ratio of 15.05 and an enterprise value-to-EBITDA ratio of 8.21 suggest the stock is trading at a moderate valuation relative to earnings and cash flow.

    The company presents a low risk of dilution, with no immediate filing-based liquidity or dilution flags detected. The valuation adjustments applied in the custom valuations do not indicate any material overvaluation or undervaluation. The low liquidity risk is supported by the company's substantial cash reserves and low debt levels.

    Recent investor relations data shows a mean price target of HKD 10.25, with a median of HKD 10.25 and a high of HKD 10.50. Analysts have issued two "buy" ratings and no "strong buy" or "hold" ratings, indicating a generally positive outlook on the stock.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 19.65 and HKD 2.23 billion in cash and equivalents.
    • Profitability is robust, with ROE of 9.48% and ROA of 8.52%, supported by high gross and operating margins.
    • The company is highly concentrated in its core pharmaceutical business and lacks geographic diversification.
    • Analysts have a positive outlook, with a mean price target of HKD 10.25 and two "buy" ratings.
    • The stock is trading at a moderate valuation with a P/E of 15.05 and EV/EBITDA of 8.21.
    • The company presents low liquidity and dilution risks, with no immediate flags detected.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$7,14
    Market cap
    HK$5.98B
    Enterprise valueⓘ
    HK$3.88B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    1.4x
    P / Tangible bookⓘ
    1.4x
    Tangible book
    HK$4.19B
    Net cashⓘ
    HK$2.10B
    Current ratioⓘ
    19.6
    Debt / equityⓘ
    0.0
    ROAⓘ
    8.5%
    ROEⓘ
    9.5%
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,59
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-22 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,59
    Revenue—no estimate—no estimate1,7B HKD
    Operating income—no estimate—no estimate587,4M HKD
    Full-year consensus mean (period as reported by source) · consensus in HKD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price targetHK$10,25 · Median HK$10,25
    Low HK$10,00High HK$10,50
    Operating income · consensus587,4M HKD
    EPS surprise
    −21,0 %
    reported vs consensus · miss
    Revenue surprise
    −9,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$10,00
    MeanHK$10,25
    MedianHK$10,25
    HighHK$10,50
    SpotHK$7,14
    +43.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin31,2 %Best in class
    Net Margin26,2 %Best in class
    ROE9,5 %Above median
    D/E0,03Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Beijing Tong Ren Tang Chinese Medicine Co Ltd Market data — financials · 2026-05-26
    • Beijing Tong Ren Tang Chinese Medicine Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Leadership

    • Chi WangChief Executive Officer, Executive Director
    • Hai Ou GuExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    3613.HKCanonical
    HKEX · HKD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage